Evidence map›Paper›PMID 34626328›Full record

ArticleSleep & breathing = Schlaf & Atmung2022

Angiotensin II receptor blocker irbesartan attenuates sleep apnea-induced cardiac apoptosis and enhances cardiac survival and Sirtuin 1 upregulation.

Pei-Ying Pai, Yi-Yuan Lin, Shao-Hong Yu, Ching-Yuang Lin, Yi-Fan Liou, Xu-Bo Wu, James K S Wong, Chih-Yang Huang, Shin-Da Lee

Abstract read
PubMed Publisher
In one paragraph

Article in Sleep & breathing = Schlaf & Atmung, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Pei-Ying Pai *Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan.
Yi-Yuan Lin *Department of Exercise and Health Science, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.
Shao-Hong YuCollege of Rehabilitation, Shandong University of Traditional Chinese Medicine, Shandong, China.
Ching-Yuang LinGraduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan.
Yi-Fan LiouDivision of Cardiology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Xu-Bo WuDepartment of Rehabilitation, Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
James K S WongDepartment of Cardiology, Asia University Hospital, Taichung, Taiwan.
Chih-Yang Huang *Graduate Institute of Chinese Medical Science, China Medical University, Taichung, Taiwan.
Shin-Da Lee *Department of Rehabilitation, Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China. shinda@mail.cmu.edu.tw.ORCID 0000-0002-8393-8349
Asia University · TWChina Medical University · TWNational Taipei University of Nursing and Health Science · TWShandong University of Traditional Chinese Medicine · CNShanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe purpose of this study was to investigate whether or not angiotensin II type 1 receptor blocker irbesartan (ARB) with a partial agonist of PPAR-γ could protect against chronic nocturnal intermittent hypoxia (CIH)-induced cardiac Fas/FasL-mediated to mitochondria-mediated apoptosis.

methodsSprague-Dawley rats were in a normoxic control group (CON-G), or rats were in a chronic nocturnal intermittent hypoxia group (HP-G, from 3 to 7% oxygen versus 21% oxygen per forty seconds cycle, nocturnally 8 h per day for 1 month), or rats were in a chronic nocturnal intermittent hypoxia group pretreated with ARB (50 mg/kg/day, S.C.) (ARB-HP-G). Echocardiography, H&E staining, TUNEL staining, and Western blotting were measured in the left ventricle.

resultsHypoxia-induced SIRT1 degradation, Fas receptors, FADD, active caspase-8 and caspase-3 (Fas/FasL apoptotic pathway) and Bax, tBid, active caspase-9 and -3 (mitochondrial apoptotic pathway) and TUNEL-positive apoptosis were reduced in ARB-HP-G when compared with HP-G. IGF-I, IGF1 receptor, p-PI3k, p-Akt, Bcl2, and Bcl-XL (IGF1/PI3K/AKT pro-survival pathway) were increased in ARB-HP-G compared to HP-G.

conclusionsOur findings suggest that the ARB may prevent cardiac Fas/FasL to mitochondrial apoptotic pathways and enhance cardiac IGF1/PI3K/AKT pro-survival pathway in the sleep apnea model associated with JNK de-activation and SIRT1 upregulation. ARB prevents chronic sleep apnea-enhanced cardiac apoptosis via enhancing survival pathways.

Indexed as

Sirtuin 1Sleep Apnea SyndromesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAnimalsApoptosisHypoxiaIrbesartanMyocardiumOxygenPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRatsRats, Sprague-DawleyUp-RegulationAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsIrbesartanOxygenPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSirtuin 1ARBsCaspaseCell deathHeartHypoxiaPeroxisome proliferator-activated receptor-γ

Identifiers

PMID34626328
OpenAlexW3204296883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.